Inaktiver Wert

Andere Sprachen Ra Pharmaceuticals, Inc.

Aktien

A2DFYM

US74933V1089

Biotechnologie

Andere Sprachen

Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P TMI Index	03.04.20
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Global BMI Index	03.04.20
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Biotechnology Select Industry Index	03.04.20
RA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	02.04.20
UCB SA completed the acquisition of Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.	02.04.20
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	31.03.20
RA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	16.03.20
Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day and Joins Global Movement to Raise Awareness for Rare Diseases	02.03.20
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	28.02.20
Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases	28.02.20
Ra Pharmaceuticals : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update	27.02.20
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	27.02.20
RA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	27.02.20
Ra Pharmaceuticals : Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	18.02.20
Ra Pharmaceuticals, Inc. Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	18.02.20
Ra Pharmaceuticals : Announces Clearance of IND Application for the HEALEY ALS Platform Trial	22.01.20
Ra Pharmaceuticals, Inc. Announces Clearance of IND Application for the HEALEY ALS Platform Trial	22.01.20
RA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	18.12.19
Ra Pharmaceuticals : Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	04.12.19
Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	04.12.19
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	25.11.19
Ra Pharmaceuticals : Reports Third Quarter 2019 Financial Results and Provides Corporate Update	07.11.19
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	07.11.19
RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX	15.10.19
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm	10.10.19

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ra Pharmaceuticals, Inc.

Aktien

A2DFYM

US74933V1089

Biotechnologie

Andere Sprachen

Filter